Targeted Therapy
Approved for: NSCLC
Biomarker: PD-L1
Nivolumab (Opdivo/Opdivo Injection) is an FDA-approved treatment for non-small cell lung cancer (NSCLC). It is used:
- As first-line therapy with ipilimumab in adults whose cancer is metastatic and has the PD-L1 protein but does not have mutations in the EGFR or ALK gene.
- As first-line therapy with ipilimumab and platinum chemotherapy in adults whose cancer is metastatic or recurrent but does not have mutations in the EGFR or ALK gene.
- In patients whose cancer is metastatic and has gotten worse during or after treatment with platinum chemotherapy.
- Patients whose cancer has a mutation in the EGFR or ALK gene should receive nivolumab only if their disease got worse after treatment with FDA-approved therapy for these gene mutations.
